Table 2.
Patient characteristics: paired diagnostic and posttreatment samples.
| Patient characteristics (n = 10) | Patient no. (%) |
|---|---|
| Age at diagnosis | |
| Median (range) | 56 (53–63) |
| Gender | |
| Male | 6 (60) |
| Immunoglobulin (Ig) isotype | |
| IgG | 5 (50) |
| IgA | 2 (20) |
| Light chains only | 3 (30) |
| Light chain isotype | |
| Kappa | 7 (70) |
| Lambda | 3 (30) |
| IMWG cytogenetics risk | |
| Standard risk | 5 (50) |
| High risk | 5 (50) |
| IMWG ISS staging | |
| I | 4 (40) |
| II | 5 (50) |
| III | 1 (10) |
| PC % in diagnostic BM biopsy | |
| Median (range) | 70% (13–80) |
| Line of therapy at treatment | |
| 1 | 10 (100) |
| Induction therapy | |
| KCD | 10 (100) |
| PC % at D100 BM biopsy posttreatment | |
| Median (range) | 0.5% (0–10) |
Abbreviations: C, cyclophosphamide; D, dexamethasone; D100, day 100; K, carfilzomib; PC, plasma cell.